← Back

Pulmatrix Inc

Pulmatrix, Inc. is a biopharmaceutical company focused on developing novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform that enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It is developing PUR1800, a narrow spectrum kinase inhibitor that completed Phase 1b clinical trials for acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine in Phase 1 for acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Country
Price · split & dividend adjusted
News & notes moving PULM
PULM▼

Halper Sadeh LLC Investigates SLP, HUN, OLN, PULM Deals for Shareholder Fairness

Halper Sadeh LLC, an investor rights law firm, is investigating Simulations Plus, Huntsman Corporation, Olin Corporation, and Pulmatrix for potential violations of federal securities laws or breaches of fiduciary duties in their proposed transactions. The investigations cover Simulations Plus's sale to Altaris affiliates for $18.50 per share, Huntsman's sale to Olin for 0.5476 Olin shares per Huntsman share, Olin's merger with Huntsman where Olin shareholders would own about 54.5% of the combined company, and Pulmatrix's merger with Eos SENOLYTIX where Pulmatrix stockholders would own about 6% of the combined company. The firm may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.
HUN · Capital · Negative Investigation into potential violations in Huntsman's sale to Olin may reduce deal value or impose additional costs.
OLN · Capital · Negative Investigation into Olin's merger with Huntsman may lead to increased consideration or other relief, potentially diluting Olin shareholders.
PULM · Capital · Negative Investigation into Pulmatrix's merger with Eos SENOLYTIX may seek increased consideration or additional disclosures, negatively impacting deal terms.
SLP · Capital · Negative Investigation into Simulations Plus's sale to Altaris for $18.50 per share may seek higher price or additional relief, creating uncertainty.
Read original ↗
GlobeNewswire·86dRead more →